Gilbert’s syndrome may predict the favorable outcome of antiviral therapy in patients with HDV infection

Blinov D.E.; Kuhareva E.I.; Tarasova O.I.; Aleksandrova M.R.; Politidis R.R.

doi:https://doi.org/10.17116/dokgastro2022110115

Blinov D.E.

Peoples’ Friendship University of Russia

Kuhareva E.I.

Peoples’ Friendship University of Russia

Tarasova O.I.

Peoples’ Friendship University of Russia

Aleksandrova M.R.

Peoples’ Friendship University of Russia

Politidis R.R.

Peoples’ Friendship University of Russia

Gilbert’s syndrome may predict the favorable outcome of antiviral therapy in patients with HDV infection

Authors:

Blinov D.E., Kuhareva E.I., Tarasova O.I., Aleksandrova M.R., Politidis R.R.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2022;11(1): 5‑12

DOI: 10.17116/dokgastro2022110115

Read: 2124 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Blinov DE, Kuhareva EI, Tarasova OI, Aleksandrova MR, Politidis RR. Gilbert’s syndrome may predict the favorable outcome of antiviral therapy in patients with HDV infection. Russian Journal of Evidence-Based Gastroenterology. 2022;11(1):5‑12. (In Russ.)
https://doi.org/10.17116/dokgastro2022110115

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)

Использование инфографики авторами научных работ

Close metadata

AIM

To assess the course of chronic HDV infection during therapy with nucleoside analogs in patients with Gilbert’s syndrome.

MATERIALS AND METHODS

The prospective study included 27 patients with chronic hepatitis D (CHD) observed at the Ogurtsov P.P. Liver Research Center (Moscow) from 2018 to 2021. Patients were prescribed antiviral therapy (HTP) — tenofovir 300 mg daily. Depending on Gilbert’s syndrome (GS), patients were divided into two groups. The dynamics of transaminase levels, the amount of HBsAg, HBV viral load, HDV RNA, and liver fibrosis were evaluated. The Wilcoxon, chi-squared, F-test, and odds ratio were used for statistical analysis.

RESULTS

In patients with chronic hepatitis D and Gilbert’s syndrome, a statistically significant decrease in the level of transaminases (p=0.04), HBsAg concentration (p<0.001), HBV DNA (p<0.001), and the risk of liver fibrosis progression by 2.3 times (OR=2.3, 95% CI 1.147—5.211; p<0.05) were observed after administration of tenofovir 300 mg daily.

CONCLUSION

Gilbert’s syndrome may predict the favorable outcome of tenofovir therapy in patients with HDV infection.

Keywords:

chronic hepatitis D

gilbert’s syndrome

liver fibrosis

nucleosides

tenofovir

Authors:

Blinov D.E.

Peoples’ Friendship University of Russia

Kuhareva E.I.

Peoples’ Friendship University of Russia

Tarasova O.I.

Peoples’ Friendship University of Russia

Aleksandrova M.R.

Peoples’ Friendship University of Russia

Politidis R.R.

Peoples’ Friendship University of Russia

Received:

08.12.2021

Accepted:

27.01.2022

Close metadata

References:

Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997-1003. https://doi.org/10.1136/gut.18.12.997
Isaeva OV, Kyuregyan KK. Viral hepatitis delta: an underestimated threat. Infekcionnye bolezni: novosti, mneniya, obuchenie. 2019;8(2):72-79. (In Russ.). https://doi.org/10.24411/2305-3496-2019-12010
Hercun J, Koh C, Heller T. Hepatitis Delta. Gastroenterology Clinics of North America. 2020;49(2):239-252. https://doi.org/10.1016/j.gtc.2020.01.004
Wranke A, Heidrich B, Ernst S, Serrano BC, Caruntu FA, Curescu MG, Yalcin K, Gurel S, Zeuzem S, Erhardt A, Luth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group. Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. PLoS ONE. 2014;9(7):e101002. https://doi.org/10.1371/journal.pone.0101002
Volz T, Allweiss L, ḾBarek MB, Warlich M, Lohse AW, Pollok JM, Jörg M, Alexandrov A, Urban S, Jörg P, Lütgehetmann M, Dandri M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. Journal of Hepatology. 2013;58(5):861-867. https://doi.org/10.1016/j.jhep.2012.12.008
Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, Karatayli S, Bozdayi AM, Koh C, Heller T, Idilman R, Glenn JS. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study. Hepatology. 2018;67(4):1224-1236. https://doi.org/10.1002/hep.29658
Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology. 2017;2(12):877-889. https://doi.org/10.1016/s2468-1253(17)30288-1
Ivashkin VT, Yushchuk ND, Maevskaya MV, Znojko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YuV, Maev IV, Pavlov ChS, Fedos’ina EA, Bueverov AO, Abdurahmanov DT, Malyshev NA, Nikitin IG, Mojsyuk YaG, Lapina TL, Truhmanov AS, Kozhevnikova GM, Zhdanov KV, Rahmanova AG, Chulanov VP, Shahgil’dyan IV, Syutkin VE, Bogomolov PO. Clinical recommendations of the Gastroenterological Association and the Russian Society for the Study of the Liver for the diagnosis and treatment of adult patients with hepatitis B. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2014;3:58-88. (In Russ.).
Klinicheskij protokol diagnostiki i lecheniya «Hronicheskij gepatit B u vzroslyh». Protokol №77 Ministerstva zdravoohraneniya Respubliki Kazahstan. Accessed September 7, 2021. (In Russ.). https://diseases.medelement.com/disease/%D1%85%D1%80%D0%BE%D0%BD%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B9-%D0%B3%D0%B5%D0%BF%D0%B0%D1%82%D0%B8%D1%82-%D0%B2-%D1%83-%D0%B2%D0%B7%D1%80%D0%BE%D1%81%D0%BB%D1%8B%D1%85-2019/16388
Schwertner HA, Vítek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. 2008;198(1):1-11. https://doi.org/10.1016/j.atherosclerosis.2008.01.001
Stocker R, Yamamoto Y, McDonagh A, Glazer A, Ames B. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043-1046. https://doi.org/10.1126/science.3029864
Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coombes JS. Improved resistance to serum oxidation in Gilbert’s syndrome: A mechanism for cardiovascular protection. Atherosclerosis. 2008; 199(2):390-396. https://doi.org/10.1016/j.atherosclerosis.2007.11.022
Radlović N, Leković Z, Mladenović M, Ristić D, Radlović V, Lekić V, Vuletić B, Djurdjević J, Gajić M. Gilbert’s syndrome in children-our experience Srpski Arhiv za Celokupno Lekarstvo. 2007;135(5-6):317-320. https://doi.org/10.2298/sarh0706317r
Landerer S, Kalthoff S, Paulusch S, Strassburg CP. UDP-glucuronosyltransferase polymorphisms affect diethylnitrosamine-induced carcinogenesis in humanized transgenic mice. Cancer Science. 2020;111(11):4266-4275. https://doi.org/10.1111/cas.14635
Sena LA, Chandel NS. Physiological Roles of Mitochondrial Reactive Oxygen Species. Molecular Cell. 2012;48(2):158-167. https://doi.org/10.1016/j.molcel.2012.09.025
Luangmonkong T, Suriguga S, Mutsaers HAM, Groothuis GMM, Olinga P, Boersema M. Targeting Oxidative Stress for the Treatment of Liver Fibrosis. Reviews of Physiology, Biochemistry and Pharmacology. 2018;175:71-102. https://doi.org/10.1007/112_2018_10
Rosca MG, Vazquez EJ, Chen Q, Kerner J, Kern TS, Hoppel CL. Oxidation of Fatty Acids Is the Source of Increased Mitochondrial Reactive Oxygen Species Production in Kidney Cortical Tubules in Early Diabetes. Diabetes. 2012;61(8):2074-2083. https://doi.org/10.2337/db11-1437
EASL European Association for the Study of the Liver. EASL European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. Journal of Hepatology. 2017;67(2):370-398. https://doi.org/10.1016/j.jhep.2017.03.021
Pavlov ChS, Glushenkov DV, Ivashkin VT. Sovremennye vozmozhnosti elastometrii, fibro- i akti-testa v diagnostike fibroza pecheni. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2008;4:43-52 (In Russ.).
Soriano V, Vispo E, Sierra-Enguita R, Mendoza Cd, Fernández-Montero JV, Labarga P, Barreiro P. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS. 2014;28:2389-2394. https://doi.org/10.1097/qad.0000000000000417
Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, Voronkova N, Schöneweis K, Pathil A, Burhenne J, Haag M, Schwab M, Haefeli WE, Wiesch JSZ, Alexandrov A, Urban S. Final results of a multicenter open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV infection. Journal of Hepatology. 2018;68(S3). https://doi.org/10.1016/S0168-8278(18)30224-1